BRECKENRIDGE PHARMACEUTICAL RECALLS PROPRANOLOL CAPSULES OVER METAL CONTAMINATION RISK
Breckenridge Pharmaceutical, Inc. has issued a nationwide voluntary recall for one lot of its Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg due to potential metal contamination.
The affected medication, distributed to wholesalers and pharmacies between October 26 and November 4, 2026, carries a risk of causing soft tissue lacerations in the oral cavity, esophagus, stomach, or intestines. While no adverse events have been reported to date, the recall was initiated after intermediate material was suspected of contamination during manufacturing by Adare Pharma Solutions.
Recall Details
-
Product: Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg (100-count bottle)
-
NDC Number: 51991-817-01
-
Lot Number:
PK25110035 -
Expiration Date: May 2029
What Consumers and Retailers Should Do
-
Consumers: Immediately stop taking the affected product and contact your healthcare provider for guidance and replacement options. Return any unused portions to the place of purchase.
-
Wholesalers and Retailers: Check your inventory immediately, quarantine any stock from lot
PK25110035, and halt all distribution.
For questions, product returns, or recall inquiries, contact Breckenridge’s service provider, Qualanex, at 1-855-736-0807 or via email at [email protected] (Monday through Friday, 9:00 a.m. to 5:00 p.m. ET). Adverse reactions can also be reported directly to the FDA’s MedWatch program.
